发明授权
- 专利标题： Activation of peptide prodrugs by hK2
- 专利标题（中）： 通过hK2激活肽前体药物
-
申请号： US10535351申请日： 2003-11-18
-
公开(公告)号： US07906477B2公开(公告)日： 2011-03-15
- 发明人: Samuel R. Denmeade , John T. Isaacs , Hans Lilja
- 申请人： Samuel R. Denmeade , John T. Isaacs , Hans Lilja
- 申请人地址： US TX San Antonio
- 专利权人： Genspera, Inc.
- 当前专利权人： Genspera, Inc.
- 当前专利权人地址： US TX San Antonio
- 代理机构： 17th Street Legal, PLLC.
- 国际申请： PCT/US03/36880 WO 20031118
- 国际公布： WO2004/046169 WO 20040603
- 主分类号： A61K38/00
- IPC分类号： A61K38/00 ; A61K38/04 ; A61K31/00 ; A61K51/00
摘要：
The invention provides novel peptide prodrugs that contain cleavage sites specifically cleaved by human kallikrein 2 (hK2). These prodrugs are useful for substantially inhibiting the non-specific toxicity of a variety of therapeutic drugs. Upon cleavage of the prodrug by hK2, the therapeutic drugs are activated and exert their toxicity. Methods for treating cell proliferative disorders are also featured in the invention.
公开/授权文献
- US20060217317A1 Activation of peptide prodrugs by hk2 公开/授权日：2006-09-28
信息查询
IPC分类:
